Alcon bought Aerie Pharmaceuticals Aerie Pharmaceuticals from 11/22/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Alcon completed its acquisition of Aerie Pharmaceuticals for $770 million, or 15.25 per share.

Aerie Pharmaceuticals

Review

Source:

{source} pictogram

investor.alcon.com

Vladimir Petenev

News editor

Write your comment first

News feed

Lenta reported for 2023 by RAS

3/29/24 LENT

X5 Retail Group moves to Russia in a forced move

3/29/24 X5

Chelyabinsk Metallurgical Plant reported for 2023 by RAS

3/29/24 CHMK

Surgutneftegaz reported for 2023 by RAS

3/29/24 SNGS

Rusolovo reported for 2023 by RAS

3/29/24 ROLO

RSC Energia reported for 2023 by RAS

3/29/24 RKKE

NovaBev reported for 2023 by RAS

3/29/24 BELU

FGC-Rosseti reported for 2023 by RAS

3/29/24 FEES

FGC-Rosseti reported for 2023 by IFRS

3/29/24 FEES

Whoosh buyback volume reached ₽60 million

3/29/24 WUSH